U.S. Food and Drug Administration Approves Opdivo<sup>®</sup> (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy

close

Get every new post delivered right to your inbox.

Original Source